OCTO-TELEMATICS
20.5.2020 10:03:03 CEST | Business Wire | Press release
OCTO, a market leader in providing smart solutions by transforming its IoT Big Data set into actionable intelligence for a sustainable connected life, is pleased to announce the launch of two products designed to support companies' return back to business as they transition to the “new normal” following the COVID-19 pandemic. These innovative solutions encourage safe self-distancing and the robust sanitization of vehicles. At the forefront of the design principals, OCTO developed products are easy to implement and manage, while being highly effective. Protecting the workforce and their livelihoods, as well as protecting customers and fostering higher levels of trust.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005174/en/
OCTO AroundMe is based on OCTO’s proven SmartTag technology that utilises the latest Bluetooth standards, OCTO’s IoT cloud platform and is compatible with both iOS and Android smartphones. OCTO AroundMe allows for easy management of social distancing in both public and private spaces, such as stores or office buildings. The pocket-sized SmartTag carried by visitors or employees continuously monitor an individual’s proximity, in this case and under government guidelines this has been automatically set to two metres. Should two people inadvertently have a distance less than two meters apart, an audible alert would remind them to keep a safe distance. The event would also be captured anonymously and stored on the cloud for reporting and analysis, to better understanding and mitigate future risk. To further mitigate any risks, using OCTO AroundMe within closed environments also allows for easy and effective crowd control and building capacity management as it stores all entry and exit information.
OCTO PurePlace uses nano technology originally developed by the National Aeronautics and Space Administration (NASA), that eliminates viruses, bacteria, fungi as well as odours and volatile organic compounds in the air and on surfaces via a purifier. It is a non-invasive solution, safe to people and all materials commonly found within vehicle interiors. As well as the purifier device, the complete OCTO PurePlace solution consists of an onboard telematics device (OCTO SmartDiag or OCTO SuperEasy) and an application compatible with iOS and Android smartphones.
OCTO PurePlace has been designed to protect drivers and passengers across corporate fleets, rental fleets, carsharing and taxi operators. It allows for the easy and effective sanitization of vehicles during a trip with intermittent self-activation and the end of each journey with a full sanitization cycle. To ensure absolute safety and confidence, before entering the vehicle, both the driver and passenger can be notified regarding the state of sanitization via a smartphone app. For the operator and the safe management of the fleet, if the sanitization is not complete, the vehicle may be temporarily suspended from public use.
ABOUT OCTO
Founded in 2002, OCTO is a leading provider of telematic services and advanced data analytics for the insurance sector, and increasingly one of the leading companies offering solutions for Fleet Telematics and Smart Mobility. With OCTO’s unique propositions already established in the field of Insurtech and Smart Mobility, OCTO continues to expand in new sectors and international markets. In the context of an increasingly connected world, OCTO’s advanced analytics and its set of IoT Big Data, generates actionable analytics giving life to a new era of Smart Telematics. Today it has over 6 million connected users and the largest database of vehicle telematics data in the world, with over 267 billion miles of driving data collected and 473,000 claims and insurance events analysed. It also manages over 400,000 vehicle rentals per month.
OCTO does not guarantee, represent or warrant that the use of a photocatalytic oxidation purifier used in the OCTO PurePlace will prevent a vehicle’s occupant(s) from contracting any type of bacteria or virus-based illness, including, but not limited to, the common cold, coronavirus or influenza.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005174/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
